690 related articles for article (PubMed ID: 28596304)
1. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Hadjiphilippou S; Ray KK
Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
Blom DJ; Dent R; Castro RC; Toth PP
Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
[TBL] [Abstract][Full Text] [Related]
5. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
Gupta S
Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 Biology and Its Role in Atherothrombosis.
Barale C; Melchionda E; Morotti A; Russo I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.
Page MM; Watts GF
Diabetes Obes Metab; 2018 Feb; 20(2):270-282. PubMed ID: 28736830
[TBL] [Abstract][Full Text] [Related]
9. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M
Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
11. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
13. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
Stein EA
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):97-105. PubMed ID: 26859553
[TBL] [Abstract][Full Text] [Related]
14. PCSK9 targets important for lipid metabolism.
Schulz R; Schlüter KD
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216
[TBL] [Abstract][Full Text] [Related]
15. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.
Del Pinto R; Grassi D; Properzi G; Desideri G; Ferri C
High Blood Press Cardiovasc Prev; 2019 Jun; 26(3):199-207. PubMed ID: 31236902
[TBL] [Abstract][Full Text] [Related]
16. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
[TBL] [Abstract][Full Text] [Related]
17. New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
Giunzioni I; Tavori H
Vasc Health Risk Manag; 2015; 11():493-501. PubMed ID: 26345307
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
Stawowy P; Just IA; Kaschina E
Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection.
Pandey P; Zhao C; Liu B
Methods Mol Biol; 2020; 2204():133-143. PubMed ID: 32710321
[TBL] [Abstract][Full Text] [Related]
20. The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia.
White CM
J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):301-308. PubMed ID: 29649884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
